Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

PURPOSE: This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer. PATIENTS AND METHODS: Mean progression-free survival (PFS) was estimated for niraparib and RS by fitt...

Descripción completa

Detalles Bibliográficos
Autores principales: Matulonis, Ursula A., Walder, Lydia, Nøttrup, Trine J., Bessette, Paul, Mahner, Sven, Gil-Martin, Marta, Kalbacher, Elsa, Ledermann, Jonathan A., Wenham, Robert M., Woie, Kathrine, Lau, Susie, Marmé, Frederik, Casado Herraez, Antonio, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lindahl, Gabriel, Benigno, Benedict, Buscema, Joseph, Travers, Karin, Guy, Holly, Mirza, Mansoor R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881097/
https://www.ncbi.nlm.nih.gov/pubmed/31518175
http://dx.doi.org/10.1200/JCO.19.00917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881097/
https://www.ncbi.nlm.nih.gov/pubmed/31518175
http://dx.doi.org/10.1200/JCO.19.00917

Ejemplares similares